Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Alpha Teknova (TKNO) stock in plain English

Free brief · no signupStart here
TKNOPublished Nov 18, 2026
Alpha Teknova Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Manufactures custom cell culture media, buffers, and chemical reagents for biopharmaceutical companies.
Assets:
Hollister, California facilityHouses primary cleanroom manufacturing operations and quality control laboratories.
Over 3,000 standard formulationsSupplies pre-formulated liquid reagents and custom molecular biology buffers.
Modular GMP cleanroomsSpecialized production suites built to manufacture clinical-grade bioprocessing reagents.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

60
OPS ScoreOperating finances
Latest quote
-0.89%$7.81
$491.28M
n/a (loss)
$45.96M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was TKNO. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Alpha Teknova (TKNO) do?

Alpha Teknova Inc (TKNO) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Manufactures custom cell culture media, buffers, and chemical reagents for biopharmaceutical companies. It is worth $491.28M on the market and sold $45.96M over the last year.

Market cap
$491.28M
P/E ratio
None (reported a loss)
Annual sales
$45.96M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 18, 2026

TKNO’s flags, in plain English

Each flag is a number from Alpha Teknova’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Insiders Hold

Insiders own 79.7% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Stupid Cash

Can pay this year's bills 3.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 45% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -34.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about TKNO

How big is Alpha Teknova?

Alpha Teknova’s market cap is $491.28M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $45.96M: what customers paid the company over the last year, before any costs.

What is TKNO’s P/E ratio?

TKNO has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with TKNO?

The business generates ongoing operating losses and depends on biotechnology customers that are trimming research budgets. That is one risk on Alpha Teknova’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Alpha Teknova’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TKNO’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card